Patient characteristics
| . | Training cohort . | P values . | Validation cohort . | P values . | ||
|---|---|---|---|---|---|---|
| MAC . | RIC . | MAC . | RIC . | |||
| n = 2223 . | n = 1873 . | n = 1098 . | n = 953 . | |||
| Median age at HCT, (range) | 57 (50-69) | 61 (50-69) | <.001 | 58 (50-69) | 60 (50-69) | <.001 |
| Age, category | ||||||
| <60 | 1373 (61.8) | 704 (37.6) | <.001 | 676 (61.6) | 398 (41.8) | <.001 |
| ≥60 | 850 (38.2) | 1169 (62.4) | 422 (38.4) | 555 (58.2) | ||
| 50-54 | 746 (33.6) | 206 (11.0) | <.001 | 368 (33.5) | 128 (13.4) | <.001 |
| 55-59 | 627 (28.2) | 498 (26.6) | 308 (28.1) | 270 (28.3) | ||
| 60-64 | 552 (24.8) | 717 (38.3) | 282 (25.7) | 350 (36.7) | ||
| 65-69 | 298 (13.4) | 452 (24.1) | 140 (12.8) | 205 (21.5) | ||
| Sex match between recipient and donor | ||||||
| Female to male | 502 (22.6) | 396 (21.1) | .272 | 251 (22.9) | 222 (23.3) | .834 |
| Others | 1721 (77.4) | 1477 (78.9) | 847 (77.1) | 731 (76.7) | ||
| Disease | ||||||
| AML | 1112 (50.0) | 769 (41.1) | <.001 | 520 (47.4) | 417 (43.8) | <.001 |
| ALL | 317 (14.3) | 448 (23.9) | 154 (14.0) | 221 (23.2) | ||
| MDS | 794 (35.7) | 656 (35.0) | 424 (38.6) | 315 (33.1) | ||
| DRI | ||||||
| Low risk | 105 (4.7) | 70 (3.7) | .274 | 57 (5.2) | 32 (3.4) | .127 |
| Intermediate risk | 1627 (73.2) | 1395 (74.5) | 804 (73.2) | 708 (74.3) | ||
| High risk | 491 (22.1) | 408 (21.8) | 237 (21.6) | 213 (22.4) | ||
| KPS | ||||||
| >80% | 1883 (84.7) | 1566 (83.6) | .344 | 952 (86.7) | 776 (81.4) | .001 |
| ≤80% | 340 (15.3) | 307 (16.4) | 146 (13.3) | 177 (18.6) | ||
| HCT-CI | ||||||
| <2 | 1578 (71.0) | 1244 (66.4) | .002 | 778 (70.9) | 652 (68.4) | .248 |
| ≥2 | 645 (29.0) | 629 (33.6) | 320 (29.1) | 301 (31.6) | ||
| Donor type | ||||||
| HLA MRD | 443 (19.9) | 309 (16.5) | <.001 | 240 (21.9) | 176 (18.5) | <.001 |
| HLA MUD | 686 (30.9) | 524 (28.0) | 343 (31.2) | 223 (23.4) | ||
| HLA MMUD | 467 (21.0) | 399 (21.3) | 230 (20.9) | 207 (21.7) | ||
| UCB | 627 (28.2) | 641 (34.2) | 285 (26.0) | 347 (36.4) | ||
| Donor source | ||||||
| Bone marrow | 1208 (54.3) | 981 (52.4) | <.001 | 614 (55.9) | 458 (48.1) | <.001 |
| Peripheral blood | 388 (17.5) | 251 (13.4) | 199 (18.1) | 148 (15.5) | ||
| UCB | 627 (28.2) | 641 (34.2) | 285 (26.0) | 347 (36.4) | ||
| GVHD prophylaxis | ||||||
| CSA-based | 621 (27.9) | 452 (24.1) | .006 | 298 (27.1) | 223 (23.4) | .053 |
| TAC-based | 1602 (72.1) | 1421 (75.9) | 800 (72.9) | 730 (76.6) | ||
| In vivo T-cell depletion | ||||||
| No | 2031 (91.4) | 1716 (91.6) | .779 | 1002 (91.3) | 870 (91.3) | 1 |
| Yes | 192 (8.6) | 157 (8.4) | 96 (8.7) | 83 (8.7) | ||
| Median y of HCT, (range) | 2015 (2008-2019) | 2014 (2008-2019) | <.001 | 2015 (2008-2019) | 2015 (2008-2019) | <.001 |
| Conditioning regimens | ||||||
| Cy/TBI-based MAC | 466 (21.0) | NA | 208 (18.9) | NA | ||
| Bu/Cy-based MAC | 269 (12.1) | NA | 137 (12.5) | NA | ||
| Flu/Bu-based MAC | 1350 (60.7) | NA | 697 (63.5) | NA | ||
| Other non-TBI MAC | 82 (3.7) | NA | 35 (3.2) | NA | ||
| Other TBI-based MAC | 56 (2.5) | NA | 21 (1.9) | NA | ||
| Flu/Bu-based RIC | NA | 746 (39.8) | NA | 390 (40.9) | ||
| Flu/Mel-based RIC | NA | 985 (52.6) | NA | 492 (51.6) | ||
| Flu/Cy-based RIC | NA | 106 (5.7) | NA | 49 (5.1) | ||
| Other RIC | NA | 36 (1.9) | NA | 22 (2.3) | ||
| . | Training cohort . | P values . | Validation cohort . | P values . | ||
|---|---|---|---|---|---|---|
| MAC . | RIC . | MAC . | RIC . | |||
| n = 2223 . | n = 1873 . | n = 1098 . | n = 953 . | |||
| Median age at HCT, (range) | 57 (50-69) | 61 (50-69) | <.001 | 58 (50-69) | 60 (50-69) | <.001 |
| Age, category | ||||||
| <60 | 1373 (61.8) | 704 (37.6) | <.001 | 676 (61.6) | 398 (41.8) | <.001 |
| ≥60 | 850 (38.2) | 1169 (62.4) | 422 (38.4) | 555 (58.2) | ||
| 50-54 | 746 (33.6) | 206 (11.0) | <.001 | 368 (33.5) | 128 (13.4) | <.001 |
| 55-59 | 627 (28.2) | 498 (26.6) | 308 (28.1) | 270 (28.3) | ||
| 60-64 | 552 (24.8) | 717 (38.3) | 282 (25.7) | 350 (36.7) | ||
| 65-69 | 298 (13.4) | 452 (24.1) | 140 (12.8) | 205 (21.5) | ||
| Sex match between recipient and donor | ||||||
| Female to male | 502 (22.6) | 396 (21.1) | .272 | 251 (22.9) | 222 (23.3) | .834 |
| Others | 1721 (77.4) | 1477 (78.9) | 847 (77.1) | 731 (76.7) | ||
| Disease | ||||||
| AML | 1112 (50.0) | 769 (41.1) | <.001 | 520 (47.4) | 417 (43.8) | <.001 |
| ALL | 317 (14.3) | 448 (23.9) | 154 (14.0) | 221 (23.2) | ||
| MDS | 794 (35.7) | 656 (35.0) | 424 (38.6) | 315 (33.1) | ||
| DRI | ||||||
| Low risk | 105 (4.7) | 70 (3.7) | .274 | 57 (5.2) | 32 (3.4) | .127 |
| Intermediate risk | 1627 (73.2) | 1395 (74.5) | 804 (73.2) | 708 (74.3) | ||
| High risk | 491 (22.1) | 408 (21.8) | 237 (21.6) | 213 (22.4) | ||
| KPS | ||||||
| >80% | 1883 (84.7) | 1566 (83.6) | .344 | 952 (86.7) | 776 (81.4) | .001 |
| ≤80% | 340 (15.3) | 307 (16.4) | 146 (13.3) | 177 (18.6) | ||
| HCT-CI | ||||||
| <2 | 1578 (71.0) | 1244 (66.4) | .002 | 778 (70.9) | 652 (68.4) | .248 |
| ≥2 | 645 (29.0) | 629 (33.6) | 320 (29.1) | 301 (31.6) | ||
| Donor type | ||||||
| HLA MRD | 443 (19.9) | 309 (16.5) | <.001 | 240 (21.9) | 176 (18.5) | <.001 |
| HLA MUD | 686 (30.9) | 524 (28.0) | 343 (31.2) | 223 (23.4) | ||
| HLA MMUD | 467 (21.0) | 399 (21.3) | 230 (20.9) | 207 (21.7) | ||
| UCB | 627 (28.2) | 641 (34.2) | 285 (26.0) | 347 (36.4) | ||
| Donor source | ||||||
| Bone marrow | 1208 (54.3) | 981 (52.4) | <.001 | 614 (55.9) | 458 (48.1) | <.001 |
| Peripheral blood | 388 (17.5) | 251 (13.4) | 199 (18.1) | 148 (15.5) | ||
| UCB | 627 (28.2) | 641 (34.2) | 285 (26.0) | 347 (36.4) | ||
| GVHD prophylaxis | ||||||
| CSA-based | 621 (27.9) | 452 (24.1) | .006 | 298 (27.1) | 223 (23.4) | .053 |
| TAC-based | 1602 (72.1) | 1421 (75.9) | 800 (72.9) | 730 (76.6) | ||
| In vivo T-cell depletion | ||||||
| No | 2031 (91.4) | 1716 (91.6) | .779 | 1002 (91.3) | 870 (91.3) | 1 |
| Yes | 192 (8.6) | 157 (8.4) | 96 (8.7) | 83 (8.7) | ||
| Median y of HCT, (range) | 2015 (2008-2019) | 2014 (2008-2019) | <.001 | 2015 (2008-2019) | 2015 (2008-2019) | <.001 |
| Conditioning regimens | ||||||
| Cy/TBI-based MAC | 466 (21.0) | NA | 208 (18.9) | NA | ||
| Bu/Cy-based MAC | 269 (12.1) | NA | 137 (12.5) | NA | ||
| Flu/Bu-based MAC | 1350 (60.7) | NA | 697 (63.5) | NA | ||
| Other non-TBI MAC | 82 (3.7) | NA | 35 (3.2) | NA | ||
| Other TBI-based MAC | 56 (2.5) | NA | 21 (1.9) | NA | ||
| Flu/Bu-based RIC | NA | 746 (39.8) | NA | 390 (40.9) | ||
| Flu/Mel-based RIC | NA | 985 (52.6) | NA | 492 (51.6) | ||
| Flu/Cy-based RIC | NA | 106 (5.7) | NA | 49 (5.1) | ||
| Other RIC | NA | 36 (1.9) | NA | 22 (2.3) | ||
CSA, cyclosporine; Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; NA, not applicable; TAC, tacrolimus.